Immunovant, Inc.
NMS: IMVTLive Quote
About Immunovant, Inc.
Healthcare
Biotechnology
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
📊 Fundamental Analysis
Immunovant, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -69.3%, which indicates that capital utilization is currently under pressure.
At a current price of $24.50, IMVT currently sits at the 70th percentile of its 52-week range (Range: $13.36 - $29.25).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$6.49B
Trailing P/E
--
Forward P/E
-9.48
Beta (5Y)
0.67
52W High
$29.25
52W Low
$13.36
Avg Volume
1.35M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App